CN111511738A - 杂芳类衍生物调节剂、其制备方法和应用 - Google Patents

杂芳类衍生物调节剂、其制备方法和应用 Download PDF

Info

Publication number
CN111511738A
CN111511738A CN201980003046.XA CN201980003046A CN111511738A CN 111511738 A CN111511738 A CN 111511738A CN 201980003046 A CN201980003046 A CN 201980003046A CN 111511738 A CN111511738 A CN 111511738A
Authority
CN
China
Prior art keywords
group
alkyl
substituted
heteroaryl
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980003046.XA
Other languages
English (en)
Other versions
CN111511738B (zh
Inventor
曾蜜
高鹏
许�鹏
程宇
李剑
蔡家强
包如迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority to CN202310015324.1A priority Critical patent/CN116003441A/zh
Priority to CN202310004737.XA priority patent/CN115925705A/zh
Publication of CN111511738A publication Critical patent/CN111511738A/zh
Application granted granted Critical
Publication of CN111511738B publication Critical patent/CN111511738B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

涉及杂芳类衍生物调节剂、其制备方法和应用。特别地，涉及通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物，及其作为Janus激酶抑制剂，在治疗炎症性相关疾病和肿瘤相关疾病的用途。

Description

PCT国内申请，说明书已公开。

Claims (40)

  1. PCT国内申请，权利要求书已公开。
CN201980003046.XA 2018-11-30 2019-11-29 杂芳类衍生物调节剂、其制备方法和应用 Active CN111511738B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202310015324.1A CN116003441A (zh) 2018-11-30 2019-11-29 杂芳类衍生物调节剂、其制备方法和应用
CN202310004737.XA CN115925705A (zh) 2018-11-30 2019-11-29 杂芳类衍生物调节剂、其制备方法和应用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2018114553573 2018-11-30
CN201811455357 2018-11-30
CN201910351595 2019-04-28
CN2019103515958 2019-04-28
CN2019111755879 2019-11-26
CN201911175587 2019-11-26
PCT/CN2019/121944 WO2020108613A1 (zh) 2018-11-30 2019-11-29 杂芳类衍生物调节剂、其制备方法和应用

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202310015324.1A Division CN116003441A (zh) 2018-11-30 2019-11-29 杂芳类衍生物调节剂、其制备方法和应用
CN202310004737.XA Division CN115925705A (zh) 2018-11-30 2019-11-29 杂芳类衍生物调节剂、其制备方法和应用

Publications (2)

Publication Number Publication Date
CN111511738A true CN111511738A (zh) 2020-08-07
CN111511738B CN111511738B (zh) 2023-01-20

Family

ID=70851917

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202310015324.1A Pending CN116003441A (zh) 2018-11-30 2019-11-29 杂芳类衍生物调节剂、其制备方法和应用
CN201980003046.XA Active CN111511738B (zh) 2018-11-30 2019-11-29 杂芳类衍生物调节剂、其制备方法和应用
CN202310004737.XA Pending CN115925705A (zh) 2018-11-30 2019-11-29 杂芳类衍生物调节剂、其制备方法和应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202310015324.1A Pending CN116003441A (zh) 2018-11-30 2019-11-29 杂芳类衍生物调节剂、其制备方法和应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310004737.XA Pending CN115925705A (zh) 2018-11-30 2019-11-29 杂芳类衍生物调节剂、其制备方法和应用

Country Status (11)

Country Link
US (1) US20230043863A1 (zh)
EP (1) EP3889152A4 (zh)
JP (1) JP2022510980A (zh)
KR (1) KR20210099611A (zh)
CN (3) CN116003441A (zh)
AU (1) AU2019388929A1 (zh)
BR (1) BR112021010358A2 (zh)
CA (1) CA3121408A1 (zh)
MX (1) MX2021006283A (zh)
TW (1) TWI741423B (zh)
WO (1) WO2020108613A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116003441A (zh) * 2018-11-30 2023-04-25 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
CN116023380A (zh) * 2021-10-26 2023-04-28 沈阳药科大学 一类吡唑并嘧啶衍生物及制备方法和应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112384515A (zh) 2018-02-27 2021-02-19 因赛特公司 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
EP3818063A1 (en) 2018-07-05 2021-05-12 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
HRP20240346T1 (hr) 2019-04-24 2024-05-24 Theravance Biopharma R&D Ip, Llc Esterski i karbonatni spojevi pirimidina kao inhibitori jak-kinaze
CA3135388A1 (en) 2019-04-24 2020-10-29 Theravance Biopharma R&D Ip, Llc Pyrimidine jak inhibitors for the treatment of skin diseases
WO2021238908A1 (zh) * 2020-05-25 2021-12-02 上海翰森生物医药科技有限公司 杂芳类衍生物的盐、晶型及其制备方法
WO2022076703A1 (en) * 2020-10-09 2022-04-14 Janssen Biotech, Inc. Processes for preparing a pan-jak inhibitor and related intermediate compounds
WO2022194191A1 (en) * 2021-03-16 2022-09-22 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of kras g12d
PE20240327A1 (es) 2021-04-13 2024-02-22 Nuvalent Inc Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr
JP2024524373A (ja) * 2021-06-28 2024-07-05 ブループリント メディシンズ コーポレイション Ｃｄｋ２阻害剤
WO2023011359A1 (zh) * 2021-08-05 2023-02-09 南京明德新药研发有限公司 桥环类化合物及其应用
WO2023246777A1 (en) * 2022-06-20 2023-12-28 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
CN118126043A (zh) * 2022-12-02 2024-06-04 沈阳药科大学 一种高选择性的plk4抑制剂及制备方法和应用
WO2024148089A1 (en) * 2023-01-04 2024-07-11 Blueprint Medicines Corporation Cdk2 inhibitors
WO2024148087A1 (en) * 2023-01-04 2024-07-11 Blueprint Medicines Corporation Cdk2 inhibitors
WO2024148091A1 (en) * 2023-01-04 2024-07-11 Blueprint Medicines Corporation Cdk2 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015094803A1 (en) * 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CN107667108A (zh) * 2015-05-28 2018-02-06 施万生物制药研发Ip有限责任公司 作为jak激酶抑制剂的萘啶化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE326462T1 (de) * 2000-12-21 2006-06-15 Vertex Pharma Pyrazolverbindungen als protein-kinase- inhibitoren
CN105367555B (zh) * 2014-08-07 2019-06-25 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
TWI726094B (zh) * 2016-04-28 2021-05-01 美商施萬生物製藥研發Ｉｐ有限責任公司 作為jak激酶抑制劑之嘧啶化合物
SI3672965T1 (sl) * 2017-10-27 2022-11-30 Theravance Biopharma R&D Ip, Llc Pirimidinska spojina kot zaviralec JAK-KINAZE
TWI740288B (zh) * 2018-11-27 2021-09-21 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
CN116003441A (zh) * 2018-11-30 2023-04-25 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
CA3135388A1 (en) * 2019-04-24 2020-10-29 Theravance Biopharma R&D Ip, Llc Pyrimidine jak inhibitors for the treatment of skin diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015094803A1 (en) * 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CN107667108A (zh) * 2015-05-28 2018-02-06 施万生物制药研发Ip有限责任公司 作为jak激酶抑制剂的萘啶化合物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116003441A (zh) * 2018-11-30 2023-04-25 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
CN116023380A (zh) * 2021-10-26 2023-04-28 沈阳药科大学 一类吡唑并嘧啶衍生物及制备方法和应用
CN116023380B (zh) * 2021-10-26 2024-01-23 沈阳药科大学 一类吡唑并嘧啶衍生物及制备方法和应用

Also Published As

Publication number Publication date
BR112021010358A2 (pt) 2021-08-24
CN111511738B (zh) 2023-01-20
EP3889152A1 (en) 2021-10-06
US20230043863A1 (en) 2023-02-09
MX2021006283A (es) 2021-10-22
JP2022510980A (ja) 2022-01-28
TW202033519A (zh) 2020-09-16
CN116003441A (zh) 2023-04-25
AU2019388929A1 (en) 2021-07-22
WO2020108613A1 (zh) 2020-06-04
EP3889152A4 (en) 2022-09-07
TWI741423B (zh) 2021-10-01
CA3121408A1 (en) 2020-06-04
KR20210099611A (ko) 2021-08-12
CN115925705A (zh) 2023-04-07

Similar Documents

Publication Publication Date Title
CN111511738B (zh) 杂芳类衍生物调节剂、其制备方法和应用
AU2020202707B2 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of Btk activity
CN111484480B (zh) 一种多环类衍生物抑制剂、其制备方法和应用
CN112513029B (zh) 含氮芳基磷氧化物类衍生物、其制备方法和应用
EP3969446B1 (en) Compounds for treating huntington&#39;s disease
KR101793807B1 (ko) 단백질 키나제 억제제로서의 융합된 헤테로시클릭 화합물
US8962596B2 (en) 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases
JP2022517222A (ja) Ｋｒａｓ ｇ１２ｃ阻害剤
JP5766820B2 (ja) Ｐｉ３キナーゼ阻害剤としての複素環化合物
CN113423703A (zh) 含氮杂环类衍生物调节剂、其制备方法和应用
CN112272670A (zh) 含二并环类衍生物抑制剂、其制备方法和应用
KR20190045381A (ko) Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
CN114163454A (zh) 含吡啶多环类衍生物抑制剂、其制备方法和应用
JP2016505020A (ja) Ｐｉｍキナーゼ阻害剤として有用なチアゾールカルボキサミドおよびピリジンカルボキサミド化合物
WO2010138589A1 (en) Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
CN114539245A (zh) 含嘧啶并环类衍生物调节剂、其制备方法和应用
CN112778311B (zh) 含氮并环类衍生物抑制剂、其制备方法和应用
CN117279914A (zh) Sos1抑制剂及其制备方法和应用
WO2023041049A1 (zh) 作为sos1抑制剂的杂环化合物及其用途
WO2023173016A1 (en) Kras inhibitors for treating disease
CN118510785A (zh) 一种含氮杂环化合物及其应用
CN114907358A (zh) 含吡啶多环类衍生物调节剂、其制备方法和应用
CN113717202A (zh) 杂芳类衍生物的自由碱晶型及其制备方法
CN113717194A (zh) 杂芳类衍生物的盐及其制备方法
CN115667228A (zh) 杂芳类衍生物的盐、晶型及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40028822

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant